Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2012-09-14 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2012-09-14 English
FORM 10-Q
Interim / Quarterly Report 9M 2012
2012-09-14 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the re-pricing of stock options for certain executives and directors, detailing the changes in exercise prices and the affected individuals. This is a corporate governance and management change announcement, specifically about option re-pricing approved by the Board's Executive Committee. It does not contain financial statements or quarterly/yearly financial results, nor is it a proxy solicitation or voting result announcement. The key section is Item 5.02, which relates to departure, election, or appointment of directors or officers and compensatory arrangements, fitting the Board/Management Information category. The document length is under 5,000 characters, but it contains substantive information about management decisions rather than just announcing a report publication. Therefore, the appropriate classification is Board/Management Information (MANG).
2012-09-11 English
PRIMARY DOCUMENT
Director's Dealing
2012-09-10 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'PRELIMINARY PROXY STATEMENT' and is identified as a Schedule 14A filing with the SEC. It contains detailed information about the upcoming Annual Meeting of Stockholders, including the election of directors, ratification of auditors, and a proposed amendment to the Certificate of Incorporation. It also includes voting procedures, quorum requirements, and information about principal stockholders. The content is consistent with materials sent to shareholders to solicit their votes for the Annual Meeting. This matches the definition of a Proxy Solicitation & Information Statement (PSI). The document is not an announcement of a report, nor is it a full annual report or earnings release. Therefore, the correct classification is PSI with high confidence.
2012-09-10 English
PRIMARY DOCUMENT
Director's Dealing
2012-09-10 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.